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Is This Effect Clinically Signiﬁcant?*Blake W. Nelson, David R. Van Wagoner, PHDSEE PAGE 1144U nder ischemic conditions, adenosine tri-phosphate (ATP) production is compro-mised and cell viability is challenged. A
homeostatic pathway present to reduce ATP utiliza-
tion is the reduction of calcium inﬂux and excitability
triggered by opening of ATP-sensitive potassium
(KATP) channels in the plasma membrane. These
channels are abundant in the heart, brain, pancreas,
and other tissues.
Plasma membrane KATP (pmKATP) channels are
well characterized with respect to subunit composi-
tion and pharmacology. Similar to many other ion
channels, pmKATP channels are macromolecular
complexes composed of pore subunits (Kir6.1 or
Kir6.2) through which potassium is selectively per-
meable, and which senses intracellular ATP concen-
trations via the associated sulfonylurea receptor
subunit (either SUR1A, SUR1B, SUR2A, or SUR2B,
depending on the species and tissue). Sulfonylurea
drugs (tolbutamide, glibenclamide) that block these
KATP channels interact with the SUR subunits. The
variations in subunit composition contribute to vari-
ations in sensitivity to intracellular ATP/adenosine
diphosphate reduction, lipids in the cell membrane,
and sensitivity to drugs that modulate these chan-
nels. Chamber speciﬁc variations in subunit expres-
sion have been well documented between the atria
and ventricle in the heart, and between different or-
gans (e.g., heart vs. pancreas) (1). Species differences*Editorials published in the Journal of the American College of Cardiology
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land, Ohio. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.in the distribution of the subunit composition of
these channels are also apparent, and are especially
evident in comparing mice and rats with larger spe-
cies (1).
While the structure and function of the pmKATP
channel has been quite well characterized, another
KATP channel present in the mitochondrial mem-
brane (mKATP) has been associated with car-
dioprotection during ischemia, via a modest increase
in reactive oxygen species and activation of protein
kinase C epsilon (2). Activation of mKATP has been
associated with preservation of mitochondrial struc-
ture and function, both during ischemia and during
reperfusion. While the structure and function of
pmKATP is well characterized, efforts to characterize
mKATP lagged due to challenges in determining its
molecular composition. For years, mKATP was pri-
marily characterized on the basis of low afﬁnity drugs
that increase its activity (diazoxide [DZX]) (3) or
suppress its activity (5-hydroxydecanoate and tolbu-
tamide). At higher concentrations, both DZX (w100
mmol/l) (1) and tolbutamide (1 mmol/l) (4) also modu-
late pmKATP channels. This cross-reactivity of drugs
has led to confusion about the pathophysiologic roles
of pmKATP versus mKATP channels.In this issue of the Journal, Xie et al. (5) present a
translational study in which they tested the hypoth-
esis that low-dose DZX treatment (30 mmol/l) would be
effective as a cardioprotective agent for preventing
ischemia-induced arrhythmias in diabetic adult male
rat hearts. The authors used optical imaging of ex vivo
Langendorff-perfused hearts to compare the effects of
DZX, a putative mKATP channel activator, with those
of pinacidil, a direct agonist of the pmKATP channel.
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1158Male Zucker obese diabetic rats were compared with
male Sprague Dawley and Zucker lean rats as controls.
The authors noted baseline differences in the
response to ischemia between groups, with profound
shortening of action potential duration (APD) in
nondiabetic controls versus a biphasic response
(transient APD shortening) in the diabetic animals
resulting in little change in APD. Ischemia slowed
conduction in all animals. Upon reperfusion of the
untreated hearts, 4 of 9 controls and 3 of 5 diabetic
hearts experienced sustained arrhythmias within 1
min. In all of the control and type 2 diabetes mellitus
(T2DM) rats, pinacidil, via its profound shortening of
ventricular APD, elicited ventricular arrhythmias
subsequent to 12 min of no-ﬂow global ischemia.
The authors predicted that, as a result of its impact
on mKATP, DZX would prevent ischemia-induced
arrhythmias in both T2DM and control hearts. In
contrast, they found that, while DZX did not elicit
arrhythmias during ischemia in any (0 of 9) of the
untreated or DZX-treated (0 of 7) control hearts dur-
ing ischemia, all (7 of 7) DZX treated T2DM and none
(0 of 5) untreated T2DM hearts experienced VT during
the late stages (10 to 12 min) of ischemia.
What underlies the difference in response between
control and T2DM rats? To determine whether T2DM
affected the composition of known KATP channel
subunits, the authors used quantitative PCR normal-
ized to the expression of b-actin. No differences were
detected between the Zucker lean versus diabetic
rats. A limitation is the small number of hearts (3 per
group) used in this analysis. Small differences that
might be signiﬁcant may not be detectable. The au-
thors suggest that if the differences are not at the
transcriptional level, post-translational modiﬁcations
of channel-related proteins may have a signiﬁcant
impact on their function. Diabetes is associated with
increased abundance of advanced glycation end
products, oxidant stress, and altered nitric oxide
metabolism that might lead to altered protein nitra-
tion or s-nitrosylation.
DZX is currently being evaluated for use as an
antidiabetic drug, and diabetic patients have an
increased risk of ischemic events subsequent to cor-
onary artery disease. What is the role of the mKATP
channel in this response? Is the observed proar-
rhythmia during ischemia reported by Xie et al. (5) of
clinical relevance or signiﬁcance in human subjects?
DZX is a small molecule drug that was created as an
antihypertensive agent, as a congener of hydrochlo-
rothiazide, a common diuretic drug. In a 1964 clinical
study of its antihypertensive effects, acute DZX
infusion was noted to both lower blood pressure and
promote hyperglycemia (6). The salt-sparing effectsof DZX distinguish it from related antihypertensive
medications that promote diuresis. In 1967, it was
noted that tolbutamide, a pmKATP channel antago-
nist, could block the actions of DZX (7). Thus, it may
be relevant to consider whether the effects of DZX
in diabetes are related to its interactions with the
mKATP channel, or also with the pmKATP channel. A
2012 study provided strong evidence that a potassium
channel subunit (ROMK, KCNJ1) ﬁrst described in the
kidney is the pore subunit of the mKATP channel (8),
consistent with the antihypertensive effects of DZX
being mediated by mKATP channels. However, there
is also compelling evidence that DZX can activate the
pmKATP channel (1).
The simplest conclusion is that DZX likely affects
both channels, favoring modulation of the mKATP at
low concentrations, while both channels are affected
at higher concentrations. The authors have not fully
eliminated the possibility that both channel types
contribute to the pro-arrhythmic response to is-
chemia in the T2DM rats. Whether or not humans
with T2DM have a similar sensitization to DZX cannot
easily be predicted, in the absence of direct studies.
Some studies with DZX have already been performed
in adult human hearts (9). Using similar optical
mapping techniques, DZX (300 mmol/l, 10 times
higher than in the current study [5]) shortened APD
by approximately 20% to 30% in diseased (heart
failure or myocardial infarction) atria and ventricles,
but not in nonfailing atria, suggesting an important
role for the pmKATP channel in the response (9). The
drug sensitivity of the pmKATP channel varies in
response to the levels of intracellular ATP and as a
function of channel subunit composition. That the
effects of DZX are evident in T2DM rats may be due to
a reduced capacity to generate and maintain ATP via
glycolysis (the primary supply available during
ischemia). Chamber differences in human and rodent
studies suggest that subunit differences can impact
the sensitivity to DZX. Additional studies that eval-
uate the integrated cardiac response to DZX in
diabetic humans seem warranted. Studies using
long-term exposure of cardiac myocytes derived from
inducible pluripotent stem cells to hyperglycemia
may supplement efforts to collect primary data from
the explanted hearts of subjects with T2DM.
Should development of DZX as a treatment for
T2DM be halted? The authors suggest that this may be
warranted. It would clearly be wise to retrospectively
examine the medical records of subjects treated with
DZX, and to prospectively closely monitor outcomes.
In addition, it would be logical to prospectively as-
sess the electrocardiographic changes in subjects in
response to a stress test, in which ischemia can be
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1159induced in a controlled setting, with ready access to
deﬁbrillation.
At all times, it is essential to consider the risk to the
patient as the top priority, recalling the guidance of
the Hippocratic Oath: First, do no harm.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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